Resveratrol and metabolic health in COPD: A proof-of-concept randomized controlled trial.

[1]  B. Larijani,et al.  Resveratrol supplementation significantly influences obesity measures: a systematic review and dose–response meta‐analysis of randomized controlled trials , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[2]  W. D. van Marken Lichtenbelt,et al.  Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes , 2018, Molecular metabolism.

[3]  A. Mangoni,et al.  Increased kynurenine plasma concentrations and kynurenine-tryptophan ratio in mild-to-moderate chronic obstructive pulmonary disease patients. , 2018, Biomarkers in medicine.

[4]  A. Schols,et al.  Resveratrol for patients with chronic obstructive pulmonary disease: hype or hope? , 2017, Current opinion in clinical nutrition and metabolic care.

[5]  J. Ruas,et al.  Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health , 2017, Science.

[6]  J. Jørgensen,et al.  No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial , 2017, The Journal of clinical endocrinology and metabolism.

[7]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. , 2017, American journal of respiratory and critical care medicine.

[8]  M. J. Ornstrup,et al.  Comprehensive Metabolomic Analysis in Blood, Urine, Fat, and Muscle in Men with Metabolic Syndrome: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Resveratrol after Four Months’ Treatment , 2017, International journal of molecular sciences.

[9]  P. Schrauwen,et al.  Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial , 2016, Diabetes Care.

[10]  J. Gostner,et al.  Resveratrol intake enhances indoleamine-2,3-dioxygenase activity in humans , 2016, Pharmacological reports : PR.

[11]  P. Schrauwen,et al.  Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial. , 2016, The American journal of clinical nutrition.

[12]  C. Calvo-Vargas,et al.  Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial , 2016, Obesity.

[13]  J. Long,et al.  Mitochondrial Dysfunction Launches Dexamethasone-Induced Skeletal Muscle Atrophy via AMPK/FOXO3 Signaling. , 2016, Molecular pharmaceutics.

[14]  R. Garten,et al.  Quadriceps exercise intolerance in patients with chronic obstructive pulmonary disease: the potential role of altered skeletal muscle mitochondrial respiration. , 2015, Journal of applied physiology.

[15]  P. Schrauwen,et al.  Resveratrol and obesity: Can resveratrol relieve metabolic disturbances? , 2015, Biochimica et biophysica acta.

[16]  Ina Schuppe-Koistinen,et al.  Skeletal Muscle PGC-1α1 Modulates Kynurenine Metabolism and Mediates Resilience to Stress-Induced Depression , 2014, Cell.

[17]  M. Polkey,et al.  Skeletal muscle adiposity is associated with physical activity, exercise capacity and fibre shift in COPD , 2014, European Respiratory Journal.

[18]  Dong-tao Wang,et al.  Resveratrol prevents TNF-α-induced muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in C2C12 myotubes. , 2014, International immunopharmacology.

[19]  M. Kelders,et al.  Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild-to-moderate COPD. , 2013, Journal of applied physiology.

[20]  S. Young,et al.  The effect of raising and lowering tryptophan levels on human mood and social behaviour , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.

[21]  M. Polkey,et al.  Pathways associated with reduced quadriceps oxidative fibres and endurance in COPD , 2012, European Respiratory Journal.

[22]  Alberto Tejedor,et al.  Site of mitochondrial reactive oxygen species production in skeletal muscle of chronic obstructive pulmonary disease and its relationship with exercise oxidative stress. , 2012, American journal of respiratory cell and molecular biology.

[23]  R. Zechner,et al.  Resveratrol regulates lipolysis via adipose triglyceride lipase. , 2012, The Journal of nutritional biochemistry.

[24]  P. Hasselgren,et al.  Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism. , 2012, Biochemical and biophysical research communications.

[25]  J. Auwerx,et al.  Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. , 2011, Cell metabolism.

[26]  J. Hurst,et al.  Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art , 2011, Expert review of respiratory medicine.

[27]  Soyoung Kim,et al.  Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. , 2011, Biochemical pharmacology.

[28]  T. Walle.  Bioavailability of resveratrol , 2011, Annals of the New York Academy of Sciences.

[29]  I. Tkáč,et al.  Increased Adipose Tissue Expression of Proinflammatory CD40, MKK4 and JNK in Patients with Very Severe Chronic Obstructive Pulmonary Disease , 2010, Respiration.

[30]  R. Rabinovich,et al.  Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients , 2010, Current opinion in pulmonary medicine.

[31]  Damian McEntegart,et al.  Randomization by minimization for unbalanced treatment allocation , 2009, Statistics in medicine.

[32]  A. Agustí,et al.  Abnormal mitochondrial function in locomotor and respiratory muscles of COPD patients , 2009, European Respiratory Journal.

[33]  Gerard Clarke,et al.  Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort , 2009, BMC gastroenterology.

[34]  D. Dougherty,et al.  L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications , 2009, International journal of tryptophan research : IJTR.

[35]  Joris Hoeks,et al.  Lower Intrinsic ADP-Stimulated Mitochondrial Respiration Underlies In Vivo Mitochondrial Dysfunction in Muscle of Male Type 2 Diabetic Patients , 2008, Diabetes.

[36]  A. Schols,et al.  Systemic inflammation and skeletal muscle dysfunction in chronic obstructive pulmonary disease: state of the art and novel insights in regulation of muscle plasticity. , 2007, Clinics in chest medicine.

[37]  P. Schrauwen,et al.  Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD , 2007, European Respiratory Journal.

[38]  Maurice P Zeegers,et al.  Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis , 2007, Thorax.

[39]  Joseph A. Baur,et al.  Therapeutic potential of resveratrol: the in vivo evidence , 2006, Nature Reviews Drug Discovery.

[40]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[41]  E. Wouters,et al.  Body composition and mortality in chronic obstructive pulmonary disease. , 2005, American Journal of Clinical Nutrition.

[42]  F. Maltais,et al.  Catabolic/anabolic balance and muscle wasting in patients with COPD. , 2003, Chest.

[43]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[44]  E Hultman,et al.  Diet, muscle glycogen and physical performance. , 1967, Acta physiologica Scandinavica.